Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Clinical features and diagnosis of leptomeningeal metastases from solid tumors

INTRODUCTION

Leptomeningeal metastases (carcinomatous meningitis) are a rare but frequently devastating complication of advanced cancer. Patients can present with a broad range of signs and symptoms due to involvement of multiple areas of the craniospinal axis. Diagnosis often requires a high index of suspicion and is confirmed by neuroimaging and cerebrospinal fluid analysis.

The pathophysiology, clinical manifestations, and diagnosis of leptomeningeal metastases (LM) from solid tumors will be reviewed here. The treatment of LM and leptomeningeal involvement in hematologic malignancies, especially large cell lymphomas and acute leukemias, is discussed separately. (See "Treatment of leptomeningeal metastases (carcinomatous meningitis)" and "Clinical presentation and diagnosis of secondary central nervous system lymphoma", section on 'Leptomeningeal metastasis' and "Involvement of the central nervous system with acute myeloid leukemia".)

EPIDEMIOLOGY

Leptomeningeal metastases (LM) are diagnosed in approximately 5 percent of patients with metastatic cancer [1-3], but undiagnosed or asymptomatic involvement is more common [4-10]. At autopsy, the frequency of LM averages 20 percent and is much higher with some tumor types [2,11,12]. Co-existing brain metastases are present in 50 to 80 percent of patients in modern series [13-17].

The most common solid tumors giving rise to LM are breast cancer (12 to 35 percent), lung cancer (10 to 26 percent), melanoma (5 to 25 percent), gastrointestinal malignancies (4 to 14 percent), and cancers of unknown primary (1 to 7 percent) [1-3,13]. In women with breast cancer, infiltrating lobular carcinoma has a particular predilection to metastasize to the leptomeninges [18-20]. Primary brain tumors, including low- and high-grade astrocytomas, medulloblastomas, ependymomas, pineoblastomas, and oligodendrogliomas, can infiltrate the leptomeninges or disseminate along cerebrospinal fluid (CSF) pathways [21,22].

The development of LM may also be influenced by treatment:

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: May 15, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9:225.
  2. Posner, JB. Neurologic Complications of Cancer. F.A. Davis, Philadelphia 1995.
  3. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003; 21:25.
  4. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759.
  5. Yap HY, Yap BS, Tashima CK, et al. Meningeal carcinomatosis in breast cancer. Cancer 1978; 42:283.
  6. Chamberlain MC. Carcinomatous meningitis. Arch Neurol 1997; 54:16.
  7. Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 1996; 7:773.
  8. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996; 53:626.
  9. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25:103.
  10. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38:245.
  11. Shapiro WR, Posner JB, Ushio Y, et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977; 61:733.
  12. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978; 19:579.
  13. Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastases in the MRI era. Neurology 2010; 74:1449.
  14. Lara-Medina F, Crismatt A, Villarreal-Garza C, et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J 2012; 18:233.
  15. Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012; 77:134.
  16. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012; 7:382.
  17. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10:199.
  18. Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med 1991; 115:507.
  19. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 1991; 48:28.
  20. Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110:2640.
  21. Saito R, Kumabe T, Jokura H, et al. Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol 2003; 61:227.
  22. Hukin J, Siffert J, Cohen H, et al. Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro Oncol 2003; 5:188.
  23. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972.
  24. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101:810.
  25. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005; 103:2344.
  26. Emoto S, Ishigami H, Yamaguchi H, et al. Frequent development of leptomeningeal carcinomatosis in patients with peritoneal dissemination of gastric cancer. Gastric Cancer 2011; 14:390.
  27. Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol 1997; 32:215.
  28. DeAngelis LM, Mandell LR, Thaler HT, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989; 24:798.
  29. Ahn JH, Lee SH, Kim S, et al. Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J Neurosurg 2012; 116:984.
  30. Suki D, Abouassi H, Patel AJ, et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 2008; 108:248.
  31. Suki D, Hatiboglu MA, Patel AJ, et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery 2009; 64:664.
  32. Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn) 2012; 18:328.
  33. Zhu JJ, Padillo O, Duff J, et al. Cavernous sinus and leptomeningeal metastases arising from a squamous cell carcinoma of the face: case report. Neurosurgery 2004; 54:492.
  34. Lossos A, Siegal T. Numb chin syndrome in cancer patients: etiology, response to treatment, and prognostic significance. Neurology 1992; 42:1181.
  35. Hansen K, Gjerris F, Sørensen PS. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien) 1987; 86:93.
  36. Laas R, Arnold H. Compression of the outlets of the leptomeningeal veins--the cause of intracranial plateau waves. Acta Neurochir (Wien) 1981; 58:187.
  37. Klein P, Haley EC, Wooten GF, VandenBerg SR. Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol 1989; 46:1149.
  38. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999; 246:810.
  39. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38:51.
  40. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40:435.
  41. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995; 23:233.
  42. Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol 2002; 23:817.
  43. Kleinschmidt-DeMasters BK, Damek DM. The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 2010; 96:375.
  44. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733.
  45. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001; 3:42.
  46. Hauke RJ, Tarantolo SR, Bashir RM, et al. Central nervous system Hodgkin's disease relapsing with eosinophilic pleocytosis. Leuk Lymphoma 1996; 21:173.
  47. Lossos A, Siegal T. Spinal subarachnoid hemorrhage associated with leptomeningeal metastases. J Neurooncol 1992; 12:167.
  48. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998; 50:1173.
  49. Bigner SH. Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 1992; 51:235.
  50. Hoon DS, Kuo CT, Wascher RA, et al. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 2001; 117:375.
  51. Malkin MG, Posner JB. Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases. Eur J Cancer Clin Oncol 1987; 23:1.
  52. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000; 54:1670.
  53. van Zanten AP, Twijnstra A, Ongerboer de Visser BW, et al. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991; 54:119.
  54. Castro MP, McDonald TJ, Qualman SJ, Odorisio TM. Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases from small cell carcinoma. Cancer 2001; 91:2122.
  55. Fujimaki T, Mishima K, Asai A, et al. Levels of beta-human chorionic gonadotropin in cerebrospinal fluid of patients with malignant germ cell tumor can be used to detect early recurrence and monitor the response to treatment. Jpn J Clin Oncol 2000; 30:291.
  56. Jorda M, Ganjei-Azar P, Nadji M. Cytologic characteristics of meningeal carcinomatosis: increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55:181.
  57. Bernstein WB, Kemp JD, Kim GS, Johnson VV. Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer. J Clin Oncol 2008; 26:3281.
  58. Cone LA, Koochek K, Henager HA, et al. Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review. Surg Neurol 2006; 65:372.
  59. Kosmas C, Tsavaris NB, Soukouli G, et al. Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer. Med Oncol 2005; 22:123.
  60. Walbert T, Groves MD. Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncol 2010; 6:287.
  61. van de Langerijt B, Gijtenbeek JM, de Reus HP, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 2006; 67:114.
  62. Reijneveld JC, Brandsma D, Boogerd W, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005; 65:1120.
  63. Friedberg MH, Glantz MJ, Klempner MS, et al. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998; 82:923.
  64. Katopodis N, Glantz MJ, Kim L, et al. Lipid-associated sialoprotein in the cerebrospinal fluid: association with brain malignancies. Cancer 2001; 92:856.
  65. Groves MD, Hess KR, Puduvalli VK, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009; 94:229.
  66. Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol 2012; 12:21.
  67. Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al. Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol 2013; 30:538.
  68. Patel AS, Allen JE, Dicker DT, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2011; 2:752.
  69. Nayak L, Fleisher M, Gonzalez-Espinoza R, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 2013; 80:1598.
  70. Mokri B. Spontaneous intracranial hypotension. Curr Neurol Neurosci Rep 2001; 1:109.
  71. Olsan AD, Milburn JM, Baumgarten KL, Durham HL. Leptomeningeal enhancement in a patient with proven West Nile virus infection. AJR Am J Roentgenol 2003; 181:591.
  72. Hsia AW, Katz JS, Hancock SL, Peterson K. Post-irradiation polyradiculopathy mimics leptomeningeal tumor on MRI. Neurology 2003; 60:1694.
  73. Ducray F, Guillevin R, Psimaras D, et al. Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis. Neuro Oncol 2008; 10:1035.